Avanzanite Bioscience
Avanzanite Bioscience enhances access to orphan drugs in Europe, partnering with pharma for rare disease treatments.
About Avanzanite Bioscience
Avanzanite Bioscience focuses on enhancing access to medicines for rare diseases in Europe. It operates as a commercial-stage enterprise, partnering with pharmaceutical companies like Advicenne and SIFI to facilitate the distribution and commercialization of orphan drugs. Avanzanite's collaborations extend across several European countries, including Ireland, Cyprus, Malta, Germany, and Austria, aiming to address the complexities and costs associated with the orphan drug market. The company's efforts are directed towards redefining the orphan drug landscape and unlocking new possibilities for patients suffering from rare diseases.
Company Facts
- Headquarters
- Amsterdam
- Operating Status
- active
- Company Type
- for_profit
- IPO Status
- private
- Employees
- c_00011_00050
- Funding Stage
- early_stage_venture
- Total Funding
- $37,064,020
- Last Funding Type
- series_a
- Last Funding Date
- 2025-11-18
- Website
- avanzanite.com
Industries & Categories
Advice, Health Care, Pharmaceutical
Social Links
Canonical: https://fsome.com/organization/avanzanite-bioscience-58696 · For the full interactive profile (funding rounds, investors, team, portfolio, charts), please enable JavaScript.